FTC Investigates Covetrus and MWI Animal Health Merger
Federal regulators are scrutinizing the proposed tie-up between Covetrus and MWI Animal Health over competition concerns.
The Federal Trade Commission is investigating the proposed merger between veterinary pharmacy distributor Covetrus and MWI Animal Health, according to a Bloomberg report, as antitrust regulators assess whether the deal could reduce competition in the animal health supply market.
The FTC probe signals that regulators are taking a close look at consolidation within the veterinary products and pharmaceutical distribution space, a sector that has seen growing dealmaking activity as demand for pet health services continues to rise across the United States.
Read more Apple and OpenAI Clash Over Hardware Control Strategy →
Both Covetrus and MWI Animal Health operate as major distributors of pharmaceuticals, supplies, and technology platforms to veterinary practices, meaning a combined entity could command significant market leverage over independent clinics and practitioners who rely on competitive pricing and supply options.
Antitrust scrutiny of distribution mergers has intensified under recent FTC leadership, with regulators increasingly focused on how vertical and horizontal consolidation affects downstream customers — in this case, veterinarians and, ultimately, pet owners who depend on accessible and affordable animal care.
The outcome of the FTC review could determine whether the deal proceeds as proposed, requires structural remedies such as divestitures, or faces a formal legal challenge. Continue reading at SeekingAlpha.
